Skip to main content
SpringerLink
Log in

Traitement hormonal substitutif et cancer du sein

  • Conference paper
Cancer du sein

  • 251 Accesses

Conclusion

Ces études confirment donc l’effet promoteur du THS de la ménopause sur certains cancers du sein préexistants. Le risque relatif observé est faible et il semble, en fait, que le THS gomme l’effet protecteur de la ménopause.

Le THS réduit la sensibilité et la spécificité de la mammographie, surtout dans le cadre du dépistage organisé et en cas de seins denses.

Concernant la mortalité, on observe globalement environ 20 à 30 % de réduction de celle-ci à l’exception de la Million Women Study.

Il est intéressant de noter que ce sont les associations estroprogestatives comportant des progestatifs de « synthèse » qui augmentent le risque et, jusqu’à preuve du contraire, pas les estrogènes administrés seuls ou en association avec de la progestérone micronisée.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Bonnier P, Sakr R, Bessenay F et al. (2000) Effets des traitements hormonaux substitutifs de la ménopause sur les facteurs pronostiques des cancers du sein. Gynecol Obstet Fertil: 745–53

    Google Scholar 

  2. Dupont WD, Page DL (1991) Menopausal estrogen replacement therapy and breast cancer. Arch. Intern. Med 151: 67–72

    Article  PubMed  CAS  Google Scholar 

  3. Steinberg KK, Thacker SB, Smith SJ et al. (1991) A meta-analysis of the effect of estrogen replacement therapy. JAMA 265: 1985–90

    Article  PubMed  CAS  Google Scholar 

  4. Grady D, Gebretsadik T, Kerlikowske K et al. (1997), Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85(2):304–13

    Article  Google Scholar 

  5. Sillero-Arenas M, Delgado-Rodriguez M, Rodriguez-Canteras R (1992) Menopausal hormonal replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 79: 286–94

    PubMed  CAS  Google Scholar 

  6. Colditz GA, Egan KM, Stampfer MJ (1993) Hormone replacement therapy and risk of breast cancer: results from epidemiological studies. Am J Obstet Gynecol 168: 1473–80

    PubMed  CAS  Google Scholar 

  7. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 350: 1047–59

    Article  Google Scholar 

  8. Hulley S, Grady D, Bush T et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in prostmenopausal women. JAMA 280(7): 605–13

    Article  PubMed  CAS  Google Scholar 

  9. Hulley S, Furberg C, Barrett-Connor E et al. (2002) Non cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288(1):58–66

    Article  PubMed  CAS  Google Scholar 

  10. The Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 273(3): 199–208

    Article  Google Scholar 

  11. Viscoli CM, Brass LM, Kernan WN et al. (2001) A clinical trial of estrogenreplacement therapy after ischemic stroke. N Engl J Med 345(17): 1243–9

    Article  PubMed  CAS  Google Scholar 

  12. Nachtigall MJ, Smilen SW, Nachtigall RD (1992) Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol 80: 827–30

    PubMed  CAS  Google Scholar 

  13. Women’s Health Initiative (WHI) (2002) Risks and benefits of estrogen plus progestin in healthy post menopausal women. Principal results from the Women’s health initiative randomized controlled trial. JAMA 288: 321–33

    Article  Google Scholar 

  14. Chlebowski RT, Hendrix SL, Langer RD et al. (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 289(24): 3243–53

    Article  PubMed  CAS  Google Scholar 

  15. Magnusson C, Holmberg L, Nordèn T et al. (1996) Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat 38: 325–34

    Article  PubMed  CAS  Google Scholar 

  16. Holli K, Isola J, Cuzick J (1998) Low biologic aggressveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 16: 3115–20

    PubMed  CAS  Google Scholar 

  17. Anderson GL, Limacher M, Assaf AR et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291(14): 1701–12

    Article  PubMed  CAS  Google Scholar 

  18. Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382): 419–27

    Article  PubMed  CAS  Google Scholar 

  19. Porch JV, Lee IM, Cook NR et al. (2002) Estrogen-progestin replacement therapy and breast cancer risk: the Women’s Health Study (United States). Cancer Causes Control 13(9): 847–54

    Article  PubMed  Google Scholar 

  20. Weiss LK, Burkman RT, Cushing-Haugen KL et al. (2002) Hormone replacement therapy regimens and breast cancer risk(1). Obstet Gynecol 100(6):1148–58

    Article  PubMed  CAS  Google Scholar 

  21. Olsson HL, Ingvar C, Bladstrom A (2003) Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 97(6): 1387–92

    Article  PubMed  Google Scholar 

  22. Ross RK, Paganini-Hill A, Wan PC et al. (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92: 328–32

    Article  PubMed  CAS  Google Scholar 

  23. Magnusson C, Baron JA, Correia N et al. (1999) Breast-cancer risk following long-term oestrogen-progestin-replacement therapy. Int J Cancer 81: 339–44

    Article  PubMed  CAS  Google Scholar 

  24. Newcomb PA, Titus-Ernstoff L, Egan KM et al. (2002) Postmenopausal estrogen and progestin use in relation to breast cancer risk. Hormone replacement therapy in relation to breast cancer. Cancer Epidemiol Biomarkers Prev 11(7): 593–600

    PubMed  CAS  Google Scholar 

  25. Greendale GA, Reboussin BA, Sie A et al. (1999) Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 130 (4 Pt 1): 262–9

    PubMed  CAS  Google Scholar 

  26. Lundström E, Christow A, Kersemaekers W et al. (2002) Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 186(4): 717–22

    Article  PubMed  CAS  Google Scholar 

  27. Fournier A. A Int J Cancer (sous presse)

    Google Scholar 

  28. Ettinger B, Friedman GD, Bush T et al. (1996) Reduced mortalilty associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 87: 6–12

    Article  PubMed  CAS  Google Scholar 

  29. Persson I, Yuen J, Bergkvist L et al. (1996) Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy — long-term follow-up of a Swedish cohort. Int J Cancer 67: 327–32

    Article  PubMed  CAS  Google Scholar 

  30. Hunt K, Vessey M, McPherson K (1990) Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 97: 1080–6

    PubMed  CAS  Google Scholar 

  31. Vakil DV, Morgan RW, Halliday M (1983) Exogenous estrogens and development of breast and endometrial cancer. Cancer Detect Prev 6: 415–24

    PubMed  CAS  Google Scholar 

  32. Schairer C, Gail M, Byrne C et al. (1999) Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 91: 264–70

    Article  PubMed  CAS  Google Scholar 

  33. Grodstein F, Stampfer MJ, Colditz GA et al. (1997) Postmenopausal hormone therapy and mortality. N Eng J Med 336: 1769–75

    Article  CAS  Google Scholar 

  34. Willis DB, Calle EE, Miracle-McMahill H et al. (1996) Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 7: 449–57

    Article  PubMed  CAS  Google Scholar 

  35. Sellers TA, MInk PJ, Cerhan JR et al. (1997) The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 127: 973–80

    PubMed  CAS  Google Scholar 

  36. Paganini-Hill A (1994) Morbidity and mortality changes with estrogen replacement thery. In: Lobo RA, ed. Treatment of the post-menopausal woman: basic and clinical aspects. New York: Raven Press 399–404

    Google Scholar 

  37. Sourander L, Rajala T, Räihä I et al. (1998) Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 352: 1965–9

    Article  PubMed  CAS  Google Scholar 

  38. Sturgeon SR, Schairer C, Brinton LA et al. (1995) Evidence of a healthy estrogen user survivor effect. Epidemiology 6: 227–31

    Article  PubMed  CAS  Google Scholar 

  39. Platet N, Cunat S, Chalbos D et al. (2000) Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms. Mol Endoclinol 14: 999–1009

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre des maladies du sein, Hôpital Saint-Louis, 1, avenue Claude Vellefaux, 75475, Paris Cedex 10

    M. Espié

Authors
  1. M. Espié
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag France, Paris

About this paper

Cite this paper

Espié, M. (2006). Traitement hormonal substitutif et cancer du sein. In: Cancer du sein. Springer, Paris. https://doi.org/10.1007/2-287-31109-2_1

Download citation

  • DOI: https://doi.org/10.1007/2-287-31109-2_1

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-25174-0

  • Online ISBN: 978-2-287-31109-3

Publish with us

Policies and ethics

Search

Navigation